Epilepsy (Central Nervous System) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy (Central Nervous System) – Drugs In Development, 2021, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy (Central Nervous System) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 12, 32, 29, 4, 124, 38 and 5 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 25 and 3 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

a:head Bio AG

Aadi Bioscience Inc

Accure Therapeutics SL

Advanced Neural Dynamics Inc

Advicenne SA

Aequus Pharmaceuticals Inc

AfaSci Inc

Affectis Pharmaceuticals AG

AgoneX Biopharmaceuticals Inc

AMO Pharma Ltd

Anavex Life Sciences Corp

Aphios Corp

Apteeus

Aquestive Therapeutics Inc

Aucta Pharmaceuticals LLC

Auris Medical Holding Ltd

Aurum Biosciences Ltd

Avicanna Inc

Axium Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Epilepsy - Overview

Epilepsy - Therapeutics Development

Epilepsy - Therapeutics Assessment

Epilepsy - Companies Involved in Therapeutics Development

Epilepsy - Drug Profiles

Epilepsy - Dormant Projects

Epilepsy - Discontinued Products

Epilepsy - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Epilepsy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Epilepsy – Pipeline by a:head Bio AG, 2021

Epilepsy – Pipeline by Aadi Bioscience Inc, 2021

Epilepsy – Pipeline by Accure Therapeutics SL, 2021

Epilepsy – Pipeline by Advanced Neural Dynamics Inc, 2021

Epilepsy – Pipeline by Advicenne SA, 2021

Epilepsy – Pipeline by Aequus Pharmaceuticals Inc, 2021

Epilepsy – Pipeline by AfaSci Inc, 2021

Epilepsy – Pipeline by Affectis Pharmaceuticals AG, 2021

Epilepsy – Pipeline by AgoneX Biopharmaceuticals Inc, 2021

Epilepsy – Pipeline by AMO Pharma Ltd, 2021

Epilepsy – Pipeline by Anavex Life Sciences Corp, 2021

Epilepsy – Pipeline by Aphios Corp, 2021

Epilepsy – Pipeline by Apteeus, 2021

Epilepsy – Pipeline by Aquestive Therapeutics Inc, 2021

Epilepsy – Pipeline by Aucta Pharmaceuticals LLC, 2021

Epilepsy – Pipeline by Auris Medical Holding Ltd, 2021

List of Figures

List of Figures

Number of Products under Development for Epilepsy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports